Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells
Maj-Britt Paulsohn, Klara Henrike Frahnert, Xin Fang, Carolin Schneider, Constanza Tapia Contreras, Günter Schneider, Elisabeth Heßmann, Matthias Dobbelstein
This study shows that combining KRAS and CDK4/6 inhibitors synergistically suppresses pancreatic cancer cells and organoids with KRAS mutations, with durable effects even after drug washout.
bioRxiv · Jan 11, 2025 · PreprintCancer Biology